Normalization of hyperinsulinemia by chronic opioid receptor blockade in hyperandrogenemic women

Fertility and Sterility

Volumn 86, Issue 3, 2006, Pages 651-657

  Hadžiomerović, Dijana ^a   Rabenbauer, Bernhard ^a   Wildt, Ludwig ^a  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

Author keywords

endogenous opiates; hirsutism; hyperandrogenemia; Hyperinsulinemia; naltrexone

Indexed keywords

ANDROGEN; C PEPTIDE; FOLLITROPIN; GLUCOSE; GONADOTROPIN; INSULIN; LUTEINIZING HORMONE; NALTREXONE; OPIATE ANTAGONIST; PRASTERONE SULFATE; TESTOSTERONE;

ANDROGEN BLOOD LEVEL; ARTICLE; BODY MASS; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFECT; FEMALE; HUMAN; HYPERANDROGENISM; HYPERINSULINEMIA; INSULIN RESPONSE; ORAL GLUCOSE TOLERANCE TEST; PRIORITY JOURNAL; STATISTICAL SIGNIFICANCE;

ADULT; ANDROGENS; FEMALE; HUMANS; HYPERANDROGENISM; HYPERINSULINISM; INSULIN; NALTREXONE; NARCOTIC ANTAGONISTS; RECEPTORS, OPIOID; TREATMENT OUTCOME;

EID: 33745180272     PISSN: 00150282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.fertnstert.2006.01.039     Document Type: Article

References (43)

1. Kahn C.R., Flier J.S., Bar R.S., Archer J.A., Gorden P., Martin M.M., et al. Syndromes of insulin resistance and acanthosis nigricans-insulin-receptor disorders in man. N Engl J Med 294 (1976) 739-745
2. Barbieri R.L., and Ryan K.J. Hyperandrogenism, insulin resistance, and acanthosis nigricans syndrome-a common endocrinopathy with distinct pathophysiologic features. Am J Obstet Gynecol 147 (1983) 90-101
3. Barbieri R.L. Polycystic ovarian disease. Annu Rev Med 42 (1991) 199-204
4. Poretsky L. On the paradox of insulin-induced hyperandrogenism in insulin-resistant states. Endocrinol Rev 12 (1991) 3-13
5. Poretsky L., and Kalin M.F. The gonadotropic function of insulin. Endocrinol Rev 82 (1987) 132-141
6. Lanzone A., Fulghesu A.M., Fortini A., Cutillo G., Cucinelli F., Di Simone N., et al. Effect of opiate receptor blockade on the insulin-response to oral glucose load in polycystic ovarian disease. Hum Reprod 6 (1991) 1043-1049
7. Sir-Petermann T., Alba F., Castillo T., Munoz A., Cortinez A., Maliqueo M., et al. Relationship between insulin resistance, LH secretion and ovarian morphological changes, in women with polycystic ovary syndrome. Rev Med Chil 126 (1998) 1049-1057
8. Sir-Petermann T., Lopez G., Castillo T., Calvillan M., Rabenbauer B., and Wildt L. Naltrexone effects on sensitivity and insulin secretion in hyperandrogenic women. Exp Clin Endocrinol Diabetes 106 (1998) 389-394
9. Givens J.R., Wiedemann E., Andersen R.N., and Kitabchi A.E. Beta-endorphin and beta-lipotropin plasma-levels in hirsute women-correlation with body weight. J Clin Endocrinol Metab 50 (1980) 975-976
10. Wildt L., Sir-Petermann T., Leyendecker G., Waibel-Treber S., and Rabenbauer B. Opiate antagonist treatment of ovarian failure. Hum Reprod 8 (1993) 168-174
11. Cederholm J., and Wibell L. Insulin release and peripheral sensitivity at the oral glucose tolerance test. Diabetes Res Clin Pract 10 (1990) 167-175
12. Wildt L., Leyendecker G., Sir-Petermann T., and Waibel-Treber S. Treatment with naltrexone in hypothalamic ovarian failure-induction of ovulation and pregnancy. Hum Reprod 8 (1993) 350-358
13. Ferin M. Endogenous opioid peptides and the menstrual cycle. Trends Neurosci 7 (1984) 194-196
14. Ferin M., Van Vugt D., and Wardlaw S. The hypothalamic control of the menstrual cycle and the role of endogenous opioid peptides. Recent Prog Horm Res 40 (1984) 441-485
15. Vettor R., Martini C., Manno M., Cestaro S., Federspil G., and Sicolo N. Effects of naloxone-induced opiate receptors blockade on insulin secretion in obesity. Horm Metab Res 17 (1985) 374-375
16. Givens J.R., Kurtz B.R., Kitabchi A.E., Bittle J.B., Karas J.G., Mitchell J.A., et al. Reduction of hyperinsulinemia and insulin resistance by opiate receptor blockade in the polycystic ovary syndrome with acanthosis nigricans. J Clin Endocrinol Metab 64 (1987) 377-382
17. Fruzzetti F., Bersi C., Parrini D., Ricci C., and Genazzani A.R. Effect of long-term naltrexone treatment on endocrine profile, clinical features, and insulin sensitivity in obese women with polycystic ovary syndrome. Fertil Steril 77 (2002) 936-944
18. Cucinelli F., Soranna L., Perri C., Barini A., Cento R.M., Mancuso S., et al. Use of naltrexone in postmenopausal women with exaggerated insulin secretion: a pilot study. Fertil Steril 81 (2004) 1047-1054
19. Bruni J.F., Watkins W.B., and Yen S.S. Beta-endorphin in the human pancreas. J Clin Endocrinol Metab 49 (1979) 649-651
20. Feldman M. Beta-endorphin and the endocrine pancreas-reply. N Engl J Med 309 (1983) 52
21. Giugliano D., Cozzolino D., Salvatore T., Ceriello A., and Torella R. Dual effect of beta-endorphin on insulin secretion in man. Horm Metab Res 19 (1987) 502-503
22. Watanabe R.M., Volund A., Roy S., and Bergman R.N. Prehepatic beta-cell secretion during the intravenous glucose tolerance test in humans-application of a combined model of insulin and C-peptide kinetics. J Clin Endocrinol Metab 69 (1989) 790-797
23. Bergman R.N., Finegood D.T., and Ader M. Assessment of insulin sensitivity in vivo. Endocrinol Rev 6 (1985) 45-86
24. Fulghesu A.M., Lanzone A., Cucinelli F., Caruso A., and Mancuso S. Long-term naltrexone treatment reduces the exaggerated insulin secretion in patients with polycystic ovary disease. Obstet Gynecol 82 (1993) 191-197
25. Dunaif A., and Finegood D.T. Beta-cell dysfunction independent of obesity and glucose intolerance in the polycystic ovary syndrome. J Clin Endocrinol Metab 81 (1996) 942-947
26. Marsden P.J., Murdoch A.P., and Taylor R. Tissue insulin sensitivity and body weight in polycystic ovary syndrome. Clin Endocrinol 55 (2001) 191-199
27. Dunaif A., Segal K.R., Futterweit W., and Dobrjansky A. Profound peripheral insulin resistance, independent of obesity, in polycystic ovary syndrome. Diabetes 38 (1989) 1165-1174
28. Ciampelli M., Fulghesu A.M., Cucinelli F., Pavone V., Ronsisvalle E., Guido M., et al. Impact of insulin and body mass index on metabolic and endocrine variables in polycystic ovary syndrome. Metabolism 48 (1999) 167-172
29. Guido M., Pavone V., Ciampelli M., Murgia F., Fulghesu A.M., Apa R., et al. Involvement of ovarian steroids in the opioid-mediated reduction of insulin secretion in hyperinsulinemic patients with polycystic ovary syndrome. J Clin Endocrinol Metab 83 (1998) 1742-1745
30. Holte J., Bergh T., Berne C., Wide L., and Lithell H. Restored insulin sensitivity but persistently increased early insulin secretion after weight loss in obese women with polycystic ovary syndrome. J Clin Endocrinol Metab 80 (1995) 2586-2593
31. Cohen J.C., and Hickman R. Insulin resistance and diminished glucose tolerance in powerlifters ingesting anabolic steroids. J Clin Endocrinol Metab 64 (1987) 960-963
32. Dunaif A., Green G., Futterweit W., and Dobrjansky A. Suppression of hyperandrogenism does not improve peripheral or hepatic insulin resistance in the polycystic ovary syndrome. J Clin Endocrinol Metab 70 (1990) 699-704
33. Billiar R.B., Richardson D., Schwartz R., Posner B., and Little B. Effect of chronically elevated androgen or estrogen on the glucose tolerance test and insulin response in female rhesus-monkeys. Am J Obstet Gynecol 157 (1987) 1297-1302
34. Pasquali R., Fabbri R., Venturoli S., Paradisi R., Antenucci D., and Melchionda N. Effect of weight loss and antiandrogenic therapy on sex hormone blood levels and insulin resistance in obese patients with polycystic ovaries. Am J Obstet Gynecol 154 (1986) 139-144
35. Singer F., Bhargava G., and Poretsky L. Persistent insulin resistance after normalization of androgen levels in a woman with congenital adrenal hyperplasia-a case report. J Reprod Med 34 (1989) 921-922
36. Mahabeer S., Jialal I., Norman R.J., Naidoo C., Reddi K., and Joubert S.M. Insulin and C-peptide secretion in non-obese patients with polycystic ovarian disease. Horm Metab Res 21 (1989) 502-506
37. Stout R.W. Insulin and atheroma-20-yr perspective. Diabetes Care 13 (1990) 631-654
38. Wild R.A., Applebaum-Bowden D., Demers L.M., Bartholomew M., Landis J.R., Hazzard W.R., et al. Lipoprotein lipids in women with androgen excess-independent associations with increased insulin and androgen. Clin Chem 36 (1990) 283-289
39. Papa V., Pezzino V., Costantino A., Belfiore A., Giuffrida D., Frittitta L., et al. Elevated insulin-receptor content in human breast cancer. J Clin Invest 86 (1990) 1503-1510
40. Kannel W.B., Wilson P.W., and Zhang T.J. The epidemiology of impaired glucose tolerance and hypertension. Am Heart J 121 (1991) 1268-1273
41. Legro R.S., Blanche P., Krauss R.M., and Lobo R.A. Alterations in low-density lipoprotein and high-density lipoprotein subclasses among Hispanic women with polycystic ovary syndrome: influence of insulin and genetic factors. Fertil Steril 72 (1999) 990-995
42. Dunaif A., and Legro R.S. Prevalence and predictors of risk for type 2 diabetes mellitus and impaired glucose tolerance in polycystic ovary syndrome-authors' response. J Clin Endocrinol Metab 84 (1999) 2975-2976
43. Legro R.S., Kunselman A.R., Dodson W.C., and Dunaif A. Prevalence and predictors of risk for type 2 diabetes mellitus and impaired glucose tolerance in polycystic ovary syndrome: a prospective, controlled study in 254 affected women. J Clin Endocrinol Metab 84 (1999) 165-169